- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- 新產(chǎn)品
- 聯(lián)系我們
別名: M-2951, MSC-2364447C
Evobrutinib是一種高度選擇性的BTK抑制劑,IC50為37.9 nM,具有潛在的抗腫瘤活性。
Evobrutinib Chemical Structure
CAS: 1415823-73-2
細胞系 | 實驗類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻信息 |
---|---|---|---|---|---|
Sf21 | Function assay | 1 uM | Inhibition of N-terminal His6-tagged full length human BMX expressed in Sf21 cells at 1 uM | 31368705 | |
Sf21 | Function assay | 1 uM | Inhibition of N-terminal His6-tagged human TEC (174 to end aminoacids) expressed in baculovirus infected Sf21 cells at 1 uM | 31368705 | |
THP1 | Function assay | 24 hrs | Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by HTRF assay, IC50=0.061μM | 32083858 | |
PBMC | Function assay | 60 mins | Inhibition of BTK in human PBMC cells assessed as reduction in anti-IgM-stimulated CD69 expression on B cells preincubated for 60 mins followed by goat F(ab')2 anti-human IgM stimulation and measured after overnight incubation by flow cytometry, IC50=0.061μM | 31368705 | |
B cells | Function assay | 60 mins | Inhibition of BTK in human B cells assessed as reduction in anti-IgM/IL4-stimulated CD69 expression on B cells preincubated for 60 mins followed by anti-IgM antibody/IL4 stimulation and measured after 16 hrs by flow cytometry, IC50=0.32μM | 32083858 | |
HEK293 | Function assay | Inhibition of human ERG expressed in HEK293 cells at -80 mV holding potential by HPLC analysis, Ki=3.1μM | 31368705 | ||
Sf21 | Function assay | Inhibition of N-terminal GST-tagged human EGFR (696 to end aminoacids) expressed in baculovirus infected Sf21 cells, IC50=5.8μM | 31368705 | ||
BTI-TN-5B1-4 | Function assay | Covalent binding affinity to human BTK (382 to 659 residues) expressed in baculovirus infected BTI-TN-5B1-4 insect cells by isothermal calorimetry | 31368705 | ||
點擊查看更多細胞系數(shù)據(jù) |
產(chǎn)品描述 | Evobrutinib是一種高度選擇性的BTK抑制劑,IC50為37.9 nM,具有潛在的抗腫瘤活性。 | ||
---|---|---|---|
靶點 |
|
體外研究(In Vitro) | ||||
體外研究活性 | Evobrutinib能抑制BTK的活性,阻止BCR信號通路的激活。它可通過羥基化、水解作用、O-去烷基化、葡萄苷酸化和谷胱甘肽結(jié)合代謝[2]。 |
---|
NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
---|---|---|---|---|---|
NCT05248945 | Completed | Healthy |
Merck Healthcare KGaA Darmstadt Germany an affiliate of Merck KGaA Darmstadt Germany |
January 13 2022 | Phase 1 |
NCT04546789 | Completed | Hepatic Impairment |
Merck Healthcare KGaA Darmstadt Germany an affiliate of Merck KGaA Darmstadt Germany |
September 30 2020 | Phase 1 |
NCT04314024 | Completed | Healthy |
Merck Healthcare KGaA Darmstadt Germany an affiliate of Merck KGaA Darmstadt Germany |
May 25 2020 | Phase 1 |
NCT03934502 | Completed | Healthy |
Merck Healthcare KGaA Darmstadt Germany an affiliate of Merck KGaA Darmstadt Germany |
April 15 2019 | Phase 1 |
分子量 | 429.51 | 分子式 | C25H27N5O2 |
CAS號 | 1415823-73-2 | SDF | -- |
Smiles | C=CC(=O)N1CCC(CC1)CNC2=NC=NC(=C2C3=CC=C(C=C3)OC4=CC=CC=C4)N | ||
儲存條件(自收到貨起) | 3年 -20°C 粉狀 | ||
體外溶解度 |
DMSO : 86 mg/mL ( (200.22 mM) ;DMSO吸濕會降低化合物溶解度,請使用新開封DMSO) Ethanol : 10 mg/mL (23.28 mM) Water : Insoluble |
摩爾濃度計算器 |
體內(nèi)溶解度 現(xiàn)配現(xiàn)用,請按從左到右的順序依次添加,澄清后再加入下一溶劑 |
動物體內(nèi)配方計算器 |
動物體內(nèi)配方計算器(澄清溶液)
第一步:請輸入基本實驗信息(考慮到實驗過程中的損耗,建議多配一只動物的藥量)
第二步:請輸入動物體內(nèi)配方組成(配方適用于不溶于水的藥物;不同批次藥物配方比例不同,請聯(lián)系Selleck為您提供正確的澄清溶液配方)
計算結(jié)果:
工作液濃度: mg/ml;
DMSO母液配制方法: mg 藥物溶于μL DMSO溶液(母液濃度mg/mL,注:如該濃度超過該批次藥物DMSO溶解度,請先聯(lián)系Selleck);
體內(nèi)配方配制方法:取μL DMSO母液,加入μL PEG300,混勻澄清后加入μL Tween 80,混勻澄清后加入μL ddH2O,混勻澄清。
體內(nèi)配方配制方法:取μL DMSO母液,加入μL Corn oil,混勻澄清。
注意:1. 首先保證母液是澄清的;
2.一定要按照順序依次將溶劑加入,進行下一步操作之前必須保證上一步操作得到的是澄清的溶液,可采用渦旋、超聲或水浴加熱等物理方法助溶。
在訂購、運輸、儲存和使用我們的產(chǎn)品的任何階段,您遇到的任何問題,均可以通過撥打我們的熱線電話400-668-6834,或者技術(shù)支持郵箱tech@selleck.cn,直接聯(lián)系到我們。我們會在24小時內(nèi)盡快聯(lián)系您。
如果有其他問題,請給我們留言。
* 必填項